Kroeger Christopher A. 4

What Happened
Christopher A. Kroeger, CEO of MapLight Therapeutics (MPLT), sold a total of 118,235 shares on May 18, 2026. The filing shows two open‑market sales: 118,037 shares at a weighted‑average price of $27.19 for $3,209,426 (transaction price range $26.565–$27.4347) and 198 shares at a weighted‑average price of $28.15 for $5,574 (transaction price range $27.57–$28.20). These were sales (S), not purchases.

Key Details

• Transaction date (and Form 4 filing date): May 18, 2026 (filed same day). Accession: 0001658918-26-000012.
• Shares sold: 118,037 @ $27.19 (WA) = $3,209,426; 198 @ $28.15 (WA) = $5,574. Total shares sold = 118,235; total proceeds = $3,215,000.
• Footnotes: the 118,037‑share sale was made pursuant to a Rule 10b5‑1 trading plan adopted Dec 29, 2025. Both sales report weighted‑average prices and list the per‑share price ranges; the filer offers to provide the breakdown of shares sold at each individual price on request.
• Ownership after transaction: not specified in the data provided here—see the full Form 4 for post‑trade holdings.
• Transaction code: S (sale). Filing appears timely (same‑day).

Context
Insider sales can be routine (e.g., scheduled under a 10b5‑1 plan, tax planning, diversification) and don’t by themselves indicate company performance. The presence of a 10b5‑1 plan for the larger block means at least that portion was pre‑arranged. Purchases tend to be more informative as a bullish signal; this filing documents sales only.